The present invention provides a compound as represented by formula I, or a pharmaceutically acceptable salt or ester, a prodrug, an optical isomer, a stereoisomer, or a solvate thereof. The compound provided by the present invention can be used for preparing drugs for preventing or treating hypertension, or hypertension-related diseases, or pulmonary hypertension, or pulmonary hypertension-related diseases. The compound provided by the present invention has a different mechanism from existing drugs for treating hypertension and pulmonary hypertension, thereby laying a new material foundation for the development of drugs for treating hypertension and pulmonary hypertension. ##STR00001##

The present invention provides a compound as represented by formula I, or a pharmaceutically acceptable salt or ester, a prodrug, an optical isomer, a stereoisomer, or a solvate thereof. The compound provided by the present invention can be used for preparing drugs for preventing or treating hypertension, or hypertension-related diseases, or pulmonary hypertension, or pulmonary hypertension-related diseases. The compound provided by the present invention has a different mechanism from existing drugs for treating hypertension and pulmonary hypertension, thereby laying a new material foundation for the development of drugs for treating hypertension and pulmonary hypertension. ##STR00001##

Catalyst materials for olefin metathesis reactions. The catalyst materials comprise a ruthenium phosphinimine complex. The ruthenium phosphinimine may be synthesized without bound N-heterocyclic carbene (NHC) or phosphine ligands, thereby providing significant advantageous in conversion, selectivity, and stability compared to existing ruthenium-based catalysts.

Catalyst materials for olefin metathesis reactions. The catalyst materials comprise a ruthenium phosphinimine complex. The ruthenium phosphinimine may be synthesized without bound N-heterocyclic carbene (NHC) or phosphine ligands, thereby providing significant advantageous in conversion, selectivity, and stability compared to existing ruthenium-based catalysts.

Provided is a labeling method having a step of labeling a substrate having a carbon-hydrogen bond with an oxygen isotope by using a catalyst and an oxidant produced from a hypervalent iodine compound having an ester structure and labeled water labeled with at least one oxygen isotope selected from the group consisting of .sup.17O and .sup.18O. Also provided is an oxidant for labeling that is produced from a hypervalent iodine compound having an ester structure and labeled water labeled with at least one oxygen isotope selected from the group consisting of .sup.17O and .sup.18O and labels a substrate having a carbon-hydrogen bond with an oxygen isotope in the co-presence of a catalyst.

The present invention relates to fluorine substituted CBD compounds, compositions thereof and uses thereof for the preparation of medicaments.

The present invention relates to fluorine substituted CBD compounds, compositions thereof and uses thereof for the preparation of medicaments.

Dimers of acetyl salicylic acid, including 4,4-diacetoxy-[1,1-biphenyl]-3,3-dicarboxylic acid (DAS-1) and 5,5-methylenebis(2-acetoxybenzoic acid) (DAS-2) are provided. Methods of blocking the C3 convertase stage of the alternative complement pathway, preventing formation of the membrane attack complex of complement, and preventing or treating a complement-mediated disorder in a mammal including the step of administering dimers of acetyl salicylic acid are also provided.

Dimers of acetyl salicylic acid, including 4,4-diacetoxy-[1,1-biphenyl]-3,3-dicarboxylic acid (DAS-1) and 5,5-methylenebis(2-acetoxybenzoic acid) (DAS-2) are provided. Methods of blocking the C3 convertase stage of the alternative complement pathway, preventing formation of the membrane attack complex of complement, and preventing or treating a complement-mediated disorder in a mammal including the step of administering dimers of acetyl salicylic acid are also provided.

Disclosed herein are biodegradable compositions comprising 1,3-propanediol, wherein the 1,3-propanediol in said biodegradable composition has a bio-based carbon content of about 1% to 100%. In addition, it is preferred that the 1,3-propanediol be biologically-derived, and wherein upon biodegradation, the biologically-derived 1,3-propanediol contributes no anthropogenic CO2 emissions to the atmosphere.